Singh Anand Pratap, Kumar Nitin, Raju Manthena Srinivasa, Singh Narendra Nath, Nagendrareddy Suma Gundareddy
Department of Oral Medicine and Radiology, Rungta College of Dental Sciences and Research, Bhilai, Chhattisgarh, India.
Department of Oral Medicine and Radiology, Career Institute of Dental Sciences and Hospital, Lucknow, Uttar Pradesh, India.
Dent Res J (Isfahan). 2014 Jan;11(1):109-13.
Tumor markers are substances, which quantitatively changes in serum, during the tumor development, one such tumor marker is serum β2-microglobulin (β2-m). The aim of this study was to establish the role of β2-m as a biochemical parameter for diagnosis and prognosis of oral carcinoma by estimation of serum β2-m levels in potentially malignant lesions, conditions, and oral squamous cell carcinoma.
The study was carried out on 48 subjects (16 control, 8 oral submucous fibrosis, 8 oral leukoplakia, and 16 oral squamous cell carcinoma patients of different stages), conducted at department of Oral Medicine, Kothiwal Dental College, Moradabad, India. Under aseptic precautions, 5 ml venous blood was drawn and serum was separated. Estimation of β2-m level in serum was carried out by enzyme linked immunosorbent assay. The data were analyzed by using the statistical package for social sciences (SPSS 17.0) software. Cases and controls were tested for statistical significance with one-way ANOVA with post-hoc Tukey's HSD. Values of P < 0.05 were considered significant.
The mean serum β2-m level in the control group was 1.173 ± 0.059, in potentially malignant lesions/conditions group was 1.688 ± 0.137 and in oral squamous cell carcinoma group was 2.835 ± 0.0313. This progressive increase in serum β2-m level was found to be highly significant (P value < 0.001). Results of Receiver operating characteristic analysis showed β2-m as a 100% sensitive and specific biomarker for oral squamous cell carcinoma.
The present study establishes β2-m as a specific biological tumor marker for diagnostic and prognostic evaluation of oral squamous cell carcinoma.
肿瘤标志物是在肿瘤发生发展过程中血清中含量发生定量变化的物质，血清β2-微球蛋白（β2-m）就是其中一种肿瘤标志物。本研究旨在通过检测潜在恶性病变、状况及口腔鳞状细胞癌患者血清β2-m水平，确定β2-m作为口腔癌诊断和预后生化指标的作用。
本研究在印度莫拉达巴德科蒂瓦尔牙科学院口腔医学系对48名受试者进行（16名对照者、8名口腔黏膜下纤维化患者、8名口腔白斑患者以及16名不同分期的口腔鳞状细胞癌患者）。在无菌操作下，抽取5毫升静脉血并分离血清。采用酶联免疫吸附测定法检测血清中β2-m水平。使用社会科学统计软件包（SPSS 17.0）对数据进行分析。采用单因素方差分析及事后Tukey's HSD检验病例组和对照组的统计学意义。P值<0.05被认为具有统计学意义。
对照组血清β2-m平均水平为1.173±0.059，潜在恶性病变/状况组为1.688±0.137，口腔鳞状细胞癌组为2.835±0.0313。血清β2-m水平的这种逐步升高具有高度统计学意义（P值<0.001）。受试者工作特征分析结果显示β2-m是口腔鳞状细胞癌的100%敏感且特异的生物标志物。
本研究确定β2-m为口腔鳞状细胞癌诊断和预后评估的特异性生物肿瘤标志物。
